We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets authority)PARIS, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Listing...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)PARIS, 06 nov...
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext...
Cellectis présente de multiples stratégies pour améliorer l'efficacité des cellules CAR T dans les tumeurs solides à la réunion annuelle de la SITC NEW YORK, 05 nov. 2024 (GLOBE NEWSWIRE...
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024 UCART22 and UCART20x22: enrollment ongoing, Phase 1 dataset and late-stage development strategy to be presented in...
Cellectis présente ses résultats financiers du troisième trimestre 2024 et une mise à jour de ses activités UCART22 et UCART20x22 : recrutement de patients en cours, un ensemble de données de la...
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a...
Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024 NEW YORK, 30 oct. 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), société...
Cellectis présentera des données sur des TALE Base Editors ainsi que sur son programme de thérapie génique non-virale lors du 31ème congrès annuel de l’ESGCT NEW YORK, 22 oct. 2024 (GLOBE...
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.208 | -10.297029703 | 2.02 | 2.02 | 1.798 | 533 | 1.904275 | DE |
4 | 0.124 | 7.34597156398 | 1.688 | 2.02 | 1.688 | 710 | 1.75459758 | DE |
12 | -0.268 | -12.8846153846 | 2.08 | 2.085 | 1.684 | 918 | 1.7914594 | DE |
26 | -0.6329999 | -25.889567521 | 2.4449999 | 2.4449999 | 1.636 | 1544 | 1.90256584 | DE |
52 | -0.892 | -32.9881656805 | 2.704 | 3.39 | 1.636 | 2413 | 2.4477082 | DE |
156 | -0.147 | -7.50382848392 | 1.959 | 3.39 | 0.936 | 4567 | 2.49399493 | DE |
260 | -0.147 | -7.50382848392 | 1.959 | 3.39 | 0.936 | 4567 | 2.49399493 | DE |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions